Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL -0.83%56 EV-to-OCF is 4.47 as of Aug. 01, 2026, which is 18% below its 10-year median of 5.46. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 52.11% on this metric.
The historical rank and industry rank for Australian Clinical Labs's EV-to-OCF or its related term are showing as below:
ASX:ACL'
s EV-to-OCF Range Over the Past 10 Years
Min: 2.89 Med: 5.46 Max: 7.81
Current: 4.4
During the past 6 years, the highest EV-to-OCF of Australian Clinical Labs was 7.81. The lowest was 2.89. And the median was 5.46.
ASX:ACL's EV-to-OCF is ranked better than 52.11% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.26
vs ASX:ACL: 4.40
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Australian Clinical Labs (ASX:ACL) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Australian Clinical Labs's PE Ratio (TTM) for today is calculated as:
Australian Clinical Labs's share price for today is A$2.38.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Australian Clinical Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.142.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Australian Clinical Labs EV-to-OCF Related Terms
Australian Clinical Labs EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Australian Clinical Labs's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's EV-to-OCF falls into.
Australian Clinical Labs's current Enterprise Value is A$736.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Australian Clinical Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$164.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs (ASX:ACL) has a EV-to-OCF of 4.47 as of Aug. 01, 2026. This is 18% below median its historical median of 5.46. Over the past decade, Australian Clinical Labs' EV-to-OCF has ranged from 2.89 to 7.81. According to the industry distribution chart, Australian Clinical Labs ranks #102 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 47.9%.
Is Australian Clinical Labs' EV-to-OCF too high?
Australian Clinical Labs' current EV-to-OCF of 4.47 is 18% below median its 10-year median of 5.46. Over the past 10 years, this metric has ranged from a low of 2.89 to a high of 7.81. The Medical Diagnostics & Research industry median EV-to-OCF is 6.26. Australian Clinical Labs' value of 4.47 is 28.6% below this industry median. Based on the distribution chart, Australian Clinical Labs ranks #102 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #102 out of 213 companies for EV-to-OCF. This puts Australian Clinical Labs in the upper half of its industry. The industry median EV-to-OCF is 6.26. Australian Clinical Labs' value of 4.47 is 28.6% below this benchmark. Historically, Australian Clinical Labs' own EV-to-OCF has ranged from 2.89 to 7.81 over the past decade. While the company's 10-year median is 5.46 vs. the industry median of 6.26, Australian Clinical Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.26, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current EV-to-OCF of 4.47 is 28.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current EV-to-OCF is 4.47, which is 18% below median its own 10-year median of 5.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current EV-to-OCF is 4.47, which is 18% below median its 10-year median of 5.46 and 28.6% below the Medical Diagnostics & Research industry median of 6.26. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current EV-to-OCF is 4.47 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06.
GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.
Key valuation signals for ASX:ACL:
EV-to-OCF: 4.47 (18% below median its 10-year median of 5.46)
GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
Industry Position: 28.6% below the Medical Diagnostics & Research median (#102 of 213)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score
Get the complete analysis for ASX:ACL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
